Pulmonary Hypertension

Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, leading to shortness of breath, dizziness, fainting, leg swelling and other symptoms. Having pulmonary arterial hypertension (PAH) means that one has a high blood pressure in the arteries that go from the lungs to heart. Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. The molecular mechanism of pulmonary arterial hypertension (PAH) is not known yet, but it is believed that the endothelial dysfunction results in a decrease in the synthesis of endothelium-derived vasodilators such as nitric oxide and prostacyclin. Diagnosis of the severe heart condition includes mainly Echocardiography or as per the signs and symptoms of the condition.

Related Conferences:

  1. 4th Lung & Respiratory Care Conference, August 01-03, 2016 Manchester, UK
  2. 5th Pulmonologists Meeting, November 17-18, 2016 Dubai, UAE
  3. 2nd Respiratory Medicine Conference, May 09-10, 2016 Chicago, USA
  4. 7th Cardiothoracic Conference, March 29-30, 2016 Atlanta, USA
  5. Interventional Cardiology Conference, Sept 12-14, 2016 Berlin,Germany
  6. Pulmonary Hypertension: Next Generation 2015, London, UK
  7. PHA’s International Pulmonary Hypertension Conference 2016, Dallas, USA
  8. Pulmonary Hypertension Summit 2016, Cleveland, Ohio, USA 
  9. 2016 International Pulmonary Hypertension Conference, Dallas, USA
  10. 8th Annual Meeting of the Saudi Association for Pulmonary Hypertension (SAPH) 2015, Abu Dhabi, UAE

Pulmonary hypertension (PH) is a condition that causes increased blood pressure in the pulmonary arteries and the right side of the heart. The pulmonary arteries carry blood from the heart and into the lungs. Pulmonary arterial hypertension (PAH) represents Group 1 within the Pulmonary Hypertension World Health Organisation (WHO) clinical classification system (Dana Point 2008) and is one of five such groups. The groups are divided based on aetiology. Sometimes, however, PAH occurs without any identifiable cause. This type of PAH is called idiopathic pulmonary arterial hypertension (IPAH). IPAH cannot be explained by another condition. Chronic thromboembolic pulmonary hypertension (CTEPH) has emerged as one of the leading causes of severe pulmonary hypertension. The consequence is an increased pulmonary vascular resistance resulting in pulmonary hypertension and progressive right heart failure.

    Related Conference of Pulmonary Hypertension

    October 20-21, 2016

    Global Summit on Heart Diseases and Therapeutics

    Chicago, Illinois, USA
    November 14-16, 2016

    14th International Conference on Clinical & Experimental Cardiology

    Orlando, Florida, USA
    December 08-09, 2016

    15th World Cardiac Surgery & Angiology Conference

    Philadelphia, Pennsylvania, USA
    December 05-06, 2016

    13th European Cardiology Conference

    Madrid, Spain
    December 08-10, 2016

    16th World Cardiology Congress

    Dubai, UAE
    March 15-17, 2017

    Annual Conference on Cardiology

    London, UK
    May 22-24, 2017

    World Heart Congress

    Osaka, Japan
    June 19-21, 2017

    17th Global Cardiologists Conference

    Paris, France
    August 31- September 1, 2017

    International Conference on Interventional and Molecular Cardiology

    Philadelphia, USA
    September 11-13, 2017

    2nd International Conference on Hypertension & Health Care

    Amsterdam, Netherlands
    September 11-13, 2017 Amsterdam, Netherlands

    2nd International Conference on Echocardiography

    October 17-18, 2017

    International Conference on Angiology

    Budapest, Hungary

    Pulmonary Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in